KetoSwiss AG

KetoSwiss AG is a Swiss biotechnology company based in Basel, focusing on the development and clinical testing of a novel nutraceutical/medical food for the dietary preventive therapy of higher-frequency migraines and other related neurological diseases such as Alzheimer's disease. Founded in 2017, their lead product's active substance is an endogenous metabolite – a Ketone body, which serves as an alternative fuel source for the human brain when glucose utilization or transport is compromised. The company recently secured an $800.00K Seed Round investment on 03 August 2023 from notable investors including R42, Healthspan Capital, ORTHO INNOVATIONS, Baszucki Group, and The William K. Warren Foundation. This innovative concept aligns with the growing interest in biotechnology and health care industries. KetoSwiss AG's focus on addressing metabolic dysfunctions that are common in various neurological diseases provides an intriguing investment opportunity. The company's dedication to developing preventive solutions for these prevalent health conditions demonstrates its potential for long-term success, making it a compelling prospect for venture capital firms seeking impactful investments in the biotech and healthcare sectors.